U.S. Securities and Exchange Commission
   Washington, DC

Litigation Release No. 15721 / April 24, 1998

   SECURITIES AND EXCHANGE COMMISSION v. GREG E. SKUDLARICK (United
   States District Court for the Northern District of Illinois, No. 98 C
   2421).

   The Securities and Exchange Commission announced that it filed a
   complaint today in the United States District Court for the Northern
   District of Illinois against Greg E. Skudlarick (Skudlarick) for
   violations of the antifraud provisions of the federal securities laws
   arising out of insider trading in the securities of Aksys, Ltd.
   (Aksys), a company in the business of developing and marketing
   hemodialysis products. The Complaint alleged violations of Section
   10(b) of the Securities Exchange Act of 1934 and Rule 10b-5
   thereunder. Simultaneously with the filing of the Complaint,
   Skudlarick, without admitting or denying the SEC's allegations,
   consented to a permanent injunction and agreed to pay a total of
   $11,838 in disgorgement, $11,838 in a civil penalty, and prejudgment
   interest.

   According to the Complaint, on June 4, 1997, Skudlarick, an
   independent consultant working at Aksys, Ltd. (Aksys), attended a
   meeting at Aksys during which he received material non-public
   information regarding the company's plans to delay submission of its
   personal hemodialysis system, known as the "PHD System," to the Food
   and Drug Administration for approval. On June 4, 1997 and June 5,
   1997, the Complaint alleges, Skudlarick purchased Aksys put option
   contracts while he was in possession of the material non-public
   information. The Complaint further alleges that Aksys publicly
   announced the delay on June 6, 1997, resulting in a decline in the
   price of Aksys stock, and that thereafter, on June 6, 1997 and June 7,
   1997, Skudlarick exercised some options and sold the remaining
   options, profiting by $11,838.
     _________________________________________________________________

Modified 04/24/1998